FDA授予Daiichi Sankyo的DS-8201用于HER2阳性转移性乳腺癌的突破性治疗指定 FDA授予Daiichi San 08/30/17 WednesdayBy Tokio X'press FDA, JPN Daiichi Sankyo
Bristol-Myers Squibb和Daiichi Sankyo宣布研究合作评估HER2表达乳腺癌和膀胱癌中的Opdivo®（nivolumab）和DS-8201 08/29/17 TuesdayBy Tokio X'press JPN, Pharmaceutical, USA Daiichi Sankyo
